Cargando…

Thymic epithelial tumors: Do we know all the prognostic factors?

BACKGROUND: Thymic epithelial tumors constitute a morphologically and clinically diverse group of rare neoplasm of the anterior mediastinum. METHODS: Here, we present an analysis of 188 patients diagnosed with primary thymic tumors between 1995 and 2015. The prognostic value of selected clinical and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Knetki‐Wróblewska, Magdalena, Kowalski, Dariusz M., Olszyna‐Serementa, Marta, Krzakowski, Maciej, Szołkowska, Małgorzata
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862797/ https://www.ncbi.nlm.nih.gov/pubmed/33386778 http://dx.doi.org/10.1111/1759-7714.13750

Ejemplares similares

Beta Blockers with Statins May Decrease All-Cause Mortality in Patients with Cardiovascular Diseases and Locally Advanced Unresectable Non-Small-Cell Lung Cancer after Chemoradiotherapy
por: Zaborowska-Szmit, Magdalena, et al.
Publicado: (2023)

Targeted Next-Generation Sequencing of Thymic Epithelial Tumours Revealed Pathogenic Variants in KIT, ERBB2, KRAS, and TP53 in 30% of Thymic Carcinomas
por: Szpechcinski, Adam, et al.
Publicado: (2022)

Nivolumab for Previously Treated Patients with Non-Small-Cell Lung Cancer—Daily Practice versus Clinical Trials
por: Knetki-Wróblewska, Magdalena, et al.
Publicado: (2020)

Non-Small-Cell Lung Cancer Patients with Coexistence of High PD-L1 Expression and RET Fusion—Which Path Should We Follow? Case Reports and Literature Review
por: Knetki-Wróblewska, Magdalena, et al.
Publicado: (2022)

Elderly Patients with Locally Advanced and Unresectable Non-Small-Cell Lung Cancer May Benefit from Sequential Chemoradiotherapy
por: Zaborowska-Szmit, Magdalena, et al.
Publicado: (2021)

Performance-Status Deterioration during Sequential Chemo-Radiotherapy as a Predictive Factor in Locally Advanced Non-Small Cell Lung Cancer
por: Olszyna-Serementa, Marta, et al.
Publicado: (2023)

Nivolumab or Atezolizumab in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer? A Prognostic Index Based on Data from Daily Practice
por: Knetki-Wróblewska, Magdalena, et al.
Publicado: (2023)

Efficacy of Immunotherapy in Second-Line Treatment of KRAS-Mutated Patients with Non-Small-Cell Lung Cancer—Data from Daily Practice
por: Knetki-Wróblewska, Magdalena, et al.
Publicado: (2022)

A thymoma or not a thymoma—that is the question: a case report
por: Szolkowska, Malgorzata, et al.
Publicado: (2021)

The Effectiveness of Pemetrexed Monotherapy Depending on Polymorphisms in TS and MTHFR Genes as Well as Clinical Factors in Advanced NSCLC Patients
por: Kucharczyk, Tomasz, et al.
Publicado: (2015)

Solitary fibrous tumour along with non-small-cell lung cancer and Doege-Potter syndrome
por: Piórek, Aleksandra, et al.
Publicado: (2019)

Do We Need TNM for Tracheal Cancers? Analysis of a Large Retrospective Series of Tracheal Tumors
por: Piórek, Aleksandra, et al.
Publicado: (2022)

Thymic neuroendocrine neoplasms—what we know, what we don’t know, and what to do about it
por: Lang, Matthias, et al.
Publicado: (2023)

Thymic carcinomas vs. lung carcinomas—pathologist’s perspective: extended abstract
por: Szolkowska, Malgorzata
Publicado: (2022)

Presbyopia: What We Do Know and What We Do Not Know in 2022
por: Grzybowski, Andrzej, et al.
Publicado: (2023)

Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients
por: Krawczyk, Paweł, et al.
Publicado: (2014)

Roxadustat: Do we know all the answers?
por: Li, Qiu-Yu, et al.
Publicado: (2023)

What Do We Know about Nociplastic Pain?
por: Bułdyś, Kacper, et al.
Publicado: (2023)

What do we know and when do we know it?
por: Nicholls, Anthony
Publicado: (2008)

Quasicrystals: What do we know? What do we want to know? What can we know?
por: Steurer, Walter
Publicado: (2018)

The Role of the Microbiome in Autism: All That We Know about All That We Don’t Know
por: David, Maude M.
Publicado: (2021)

All eyes on Coronavirus—What do we need to know as ophthalmologists
por: Khanna, Rohit C, et al.
Publicado: (2020)

Biogenic Silver Nanoparticles: What We Know and What Do We Need to Know?
por: Rai, Mahendra, et al.
Publicado: (2021)

Cardiovascular Complications of Systemic Therapy in Non-Small-Cell Lung Cancer
por: Zaborowska-Szmit, Magdalena, et al.
Publicado: (2020)

Cerebrospinal fluid circulation: What do we know and how do we know it?
por: Khasawneh, Ahmad H, et al.
Publicado: (2018)

Ticks and Tularemia: Do We Know What We Don't Know?
por: Zellner, Briana, et al.
Publicado: (2019)

Vaginal Aging—What We Know and What We Do Not Know
por: Szymański, Jacek K., et al.
Publicado: (2021)

Real-world clinical outcomes of first-generation and second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large cohort of European non-small-cell lung cancer patients
por: Pluzanski, Adam, et al.
Publicado: (2020)

Non-Epithelial Ovarian Cancers: How Much Do We Really Know?
por: Cheung, Alison, et al.
Publicado: (2022)

Statin Intolerance—We Know Everything, We Know Nothing
por: Banach, Maciej
Publicado: (2022)

Adherence to statin therapy: it seems we know everything, yet we do nothing
por: Banach, Maciej, et al.
Publicado: (2022)

Transmission of Ebola Viruses: What We Know and What We Do Not Know
por: Osterholm, Michael T., et al.
Publicado: (2015)

Microbiome in Multiple Sclerosis: Where Are We, What We Know and Do Not Know
por: Boziki, Marina Kleopatra, et al.
Publicado: (2020)

Statin treatment in the elderly: how much do we know?
por: Rizzo, Manfredi, et al.
Publicado: (2013)

COVID-19 and cancer: do we really know what we think we know?
por: Robinson, Andrew G., et al.
Publicado: (2020)

What do we currently know about Novichoks? The state of the art
por: Noga, Maciej, et al.
Publicado: (2022)

Sodium and brain injury: do we know what we are doing?
por: Zygun, David A
Publicado: (2009)

Multimorbidity: What do we know? What should we do?
por: Navickas, Rokas, et al.
Publicado: (2016)

How little do we know?
por: Waslekar, Sundeep
Publicado: (2007)

Do we know the limits of the heart?
por: Figueras-Coll, Marc, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_99dfm83p071mc297anchs927e9